

Applicant : Parent et al.  
Serial No. : 10/611,439  
Filed : July 1, 2003  
Page : 5 of 9

RECEIVED  
CENTRAL FAX CENTER

Attorney's Docket No.: 00986-084001 / 5099

MAR 07 2005

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-6. (Canceled)

7. (Currently amended) A conjugate comprising the reaction product of the intermediate having the formula  $P-O-CH_2-CH_2-SO_2-(CH=CH_2)_n$   $P-O-(CH_2-CH_2-SO_2-CH=CH_2)_n$ , wherein n is an integer and is at least 1, and P represents a hydrophilic biopolymer and a biologically active material capable of being covalently and nucleophilically bonded to said intermediate.

8. (Original) A conjugate according to claim 7 wherein the biologically active substance is any such substance having at least one chemical group reactive toward DVS.

9. (Original) A conjugate according to claim 8 wherein the hydrophilic biopolymer is a hyaluronan moiety or a moiety of a mixture of a hyaluronan with at least one other hydrophilic polymer.

10. (Original) A conjugate according to claim 8 wherein the biologically active material is an antineoplastic, an antibiotic, a protein, an enzyme or a peptide.

11. (Original) A conjugate according to claim 10 wherein the antineoplastic is vinblastin or paclitaxel, the antibiotic is gentamicin, the protein is alpha-interferon or cytochrome C, the enzyme is thrombin and the peptide is avidin.

12. (Original) A conjugate according to claim 9 wherein the biologically active material is alpha-interferon.

Applicant : Parent et al.  
Serial No. : 10/611,439  
Filed : July 1, 2003  
Page : 6 of 9

Attorney's Docket No.: 00986-084001 / 5099

13. (Currently amended) A conjugate according to claim 12 and having the formula ~~HA-O-~~  
~~CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-NH-INF~~ HA-O-CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-NH-INF, wherein HA  
represents a hyaluronan moiety or a moiety of a mixture of a hyaluronan with at least one other  
hydrophilic polymer, and INF represents an alpha-interferon moiety.

14-19. (Canceled)

20. (Original) A method of preparing the conjugate of claim 7 comprising reacting the  
intermediate with the biologically active material in aqueous solution at a pH of 9 or higher at a  
temperature of about 4.degree. C. in the presence of a carbonate buffer and shaken for about 24  
hours and thereafter dialyzing the reaction mixture with saline solution to remove therefrom  
unreacted biologically active material.

21. (Original) A method according to claim 20 wherein the biologically active substance is any  
such substance having at least one chemical group reactive toward DVS.

22. (Currently amended) A method according to claim 20 wherein the intermediate has the  
formula ~~P-O-CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>2</sub>-(CH=CH<sub>2</sub>)<sub>n</sub>~~ P-O-(CH<sub>2</sub>-CH<sub>2</sub>-SO<sub>2</sub>-CH=CH<sub>2</sub>)<sub>n</sub>, wherein n is an  
integer and is at least 1, and P represents a hydrophilic biopolymer and the hydrophilic  
biopolymer is a hyaluronan moiety or a moiety of a mixture of a hyaluronan with at least one  
other hydrophilic polymer.

23. (Original) A method according to claim 20 wherein the biologically active material is an  
antineoplastic, an antibiotic, a protein, an enzyme or a peptide.

24. (Original) A method according to claim 23 wherein the antineoplastic is vinblastin or  
paclitaxel, the antibiotic is gentamicin, the protein is alpha-interferon or Cytochrome C, the  
enzyme is thrombin and the peptide is avidin.

Applicant : Parent et al.  
Serial No. : 10/611,439  
Filed : July 1, 2003  
Page : 7 of 9

Attorney's Docket No.: 00986-084001 / 5099

25. (Original) A method according to claim 20 wherein the biologically active material is alpha-interferon.

26. (Original) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate according to claim 7 in a pharmacologically acceptable carrier or vehicle therefor.

27. (Original) A method of treating an animal afflicted with a neoplastic condition comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 26 to said animal.

28-31. (Canceled)